<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05117918</url>
  </required_header>
  <id_info>
    <org_study_id>21-000458</org_study_id>
    <nct_id>NCT05117918</nct_id>
  </id_info>
  <brief_title>Overactive Bladder Telemedicine Non-inferiority Trial</brief_title>
  <acronym>OAB Telemed</acronym>
  <official_title>A Prospective Study Evaluating the Feasibility of Telemedicine Use in the Overactive Bladder Clinical Care Pathway: a Non-inferiority Study Assessing Patient Satisfaction and Progression to Third Line Overactive Bladder Therapies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Los Angeles</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, Los Angeles</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study, the investigators aim to validate the telemedicine paradigm as a feasible&#xD;
      alternative to traditional in-person clinic visits for the management of overactive bladder&#xD;
      (OAB).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single-center, prospective randomized controlled trial. The study population will&#xD;
      consist of two primary cohorts stratified based on the method of follow-up, either&#xD;
      traditional in-person clinic visit or telemedicine appointment. The primary outcome will be&#xD;
      satisfaction with OAB treatment. Secondary endpoints include rate of progression to third&#xD;
      line therapies, changes in OAB symptom scores, safety, and cost. This non-inferiority trial&#xD;
      is designed to provide an alternative option for care delivery that may result in improved&#xD;
      patient satisfaction and compliance, and decreased cost, time, and travel burden for&#xD;
      patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2021</start_date>
  <completion_date type="Anticipated">January 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Patient Satisfaction</measure>
    <time_frame>1 year</time_frame>
    <description>Treatment Satisfaction Visual Analogue Scale (TS-VAS), scale scored from 0 - 100 with 100 indicating highest satisfaction</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PGII</measure>
    <time_frame>1 year</time_frame>
    <description>Patient Global impression of improvement (PGII), minimum of 0, maximum of 6 with 0 indicating the patient is most improved</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment-emergent adverse events (safety and tolerability)</measure>
    <time_frame>1 year</time_frame>
    <description>Adverse events related to treatment requiring emergency room visits, urgent care visits, hospital admissions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accumulated cost of visit to patient (Cost)</measure>
    <time_frame>1 year</time_frame>
    <description>Cost of parking, travel, and other visit-associated expenses to patient</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accumulated time of visit for patient (Time)</measure>
    <time_frame>1 year</time_frame>
    <description>Time of travel to visit, time of visit, wait time of visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overactive Bladder Symptoms</measure>
    <time_frame>1 year</time_frame>
    <description>Overactive Bladder Questionnaire Short-Form (OAB-q SF), scale from 6-36 with 36 indicating the most severe OAB symptoms</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">132</enrollment>
  <condition>Overactive Bladder</condition>
  <arm_group>
    <arm_group_label>Traditional In-Person Clinic Visit Arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients will receive overactive bladder (OAB) treatment as described in the Society for Urodynamics and Female Pelvic Medicine and Urogenital Reconstruction (SUFU) OAB clinical care pathway. These patients will have all visits in-person</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Telemedicine Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive OAB treatment as described in the SUFU OAB clinical care pathway but all visits will be performed via telemedicine</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>SUFU Clinical Care Pathway for Overactive Bladder</intervention_name>
    <description>Treatment of OAB via the SUFU clinical care pathway</description>
    <arm_group_label>Telemedicine Arm</arm_group_label>
    <arm_group_label>Traditional In-Person Clinic Visit Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Telemedicine</intervention_name>
    <description>Delivery of care via telemedicine</description>
    <arm_group_label>Telemedicine Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Idiopathic overactive bladder diagnosis, both OAB wet and OAB dry&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Active Urinary Tract Infection (UTI)&#xD;
&#xD;
          -  Stage 3 or 4 prolapse&#xD;
&#xD;
          -  Underlying neurologic condition contributing to OAB&#xD;
&#xD;
          -  Use of catheter&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>James Weinberger</last_name>
    <phone>(310) 794-7700</phone>
    <email>JMWeinberger@mednet.ucla.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James Weinberger</last_name>
      <phone>310-794-7700</phone>
      <email>JMWeinberger@mednet.ucla.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>August 18, 2021</study_first_submitted>
  <study_first_submitted_qc>November 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 11, 2021</study_first_posted>
  <last_update_submitted>November 3, 2021</last_update_submitted>
  <last_update_submitted_qc>November 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, Los Angeles</investigator_affiliation>
    <investigator_full_name>Victor W. Nitti, MD</investigator_full_name>
    <investigator_title>Professor of Urology, Chief, Division of Female Pelvic Medicine and Reconstructive Surgery</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder, Overactive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

